

Tuan Zea Tan

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/777214/publications.pdf>

Version: 2024-02-01

120
papers

5,796
citations

76326

40
h-index

88630

70
g-index

133
all docs

133
docs citations

133
times ranked

10764
citing authors

#	ARTICLE	IF	CITATIONS
1	The H. pylori CagA Oncoprotein Induces DNA Double Strand Breaks through Fanconi Anemia Pathway Downregulation and Replication Fork Collapse. International Journal of Molecular Sciences, 2022, 23, 1661.	4.1	6
2	BCG therapy downregulates HLA-I on malignant cells to subvert antitumor immune responses in bladder cancer. Journal of Clinical Investigation, 2022, 132, .	8.2	11
3	Osteopontin (OPN/SPP1), a Mediator of Tumor Progression, Is Regulated by the Mesenchymal Transcription Factor Slug/SNAI2 in Colorectal Cancer (CRC). Cells, 2022, 11, 1808.	4.1	6
4	3D genome organization in the epithelial-mesenchymal transition spectrum. Genome Biology, 2022, 23, .	8.8	10
5	TRAF4 Inhibits Bladder Cancer Progression by Promoting BMP/SMAD Signaling. Molecular Cancer Research, 2022, 20, 1516-1531.	3.4	9
6	Putting the BRK on breast cancer: From molecular target to therapeutics. Theranostics, 2021, 11, 1115-1128.	10.0	14
7	Blocking Aerobic Glycolysis by Targeting Pyruvate Dehydrogenase Kinase in Combination with EGFR TKI and Ionizing Radiation Increases Therapeutic Effect in Non-Small Cell Lung Cancer Cells. Cancers, 2021, 13, 941.	3.7	20
8	SMARCA2 Is a Novel Interactor of NSD2 and Regulates Prometastatic <i>PTP4A3</i> through Chromatin Remodeling in t(4;14) Multiple Myeloma. Cancer Research, 2021, 81, 2332-2344.	0.9	10
9	Epithelial to Mesenchymal Transition Regulates Surface PD-L1 via CMTM6 and CMTM7 Induction in Breast Cancer. Cancers, 2021, 13, 1165.	3.7	24
10	Quantitative imaging of RAD51 expression as a marker of platinum resistance in ovarian cancer. EMBO Molecular Medicine, 2021, 13, e13366.	6.9	30
11	Topography of transcriptionally active chromatin in glioblastoma. Science Advances, 2021, 7, .	10.3	19
12	Cytoskeletal Dynamics in Epithelial-Mesenchymal Transition: Insights into Therapeutic Targets for Cancer Metastasis. Cancers, 2021, 13, 1882.	3.7	77
13	Doxycycline host-directed therapy in human pulmonary tuberculosis. Journal of Clinical Investigation, 2021, 131, .	8.2	27
14	A multi-ethnic analysis of immune-related gene expression signatures in patients with ovarian clear cell carcinoma. Journal of Pathology, 2021, 255, 285-295.	4.5	6
15	Epigenetic derepression converts PPAR β into a druggable target in triple-negative and endocrine-resistant breast cancers. Cell Death Discovery, 2021, 7, 265.	4.7	7
16	MicroRNA-196a promotes renal cancer cell migration and invasion by targeting BRAM1 to regulate SMAD and MAPK signaling pathways. International Journal of Biological Sciences, 2021, 17, 4254-4270.	6.4	13
17	ASLAN003, a potent dihydroorotate dehydrogenase inhibitor for differentiation of acute myeloid leukemia. Haematologica, 2020, 105, 2286-2297.	3.5	43
18	Peruvoside targets apoptosis and autophagy through MAPK Wnt/ β -catenin and PI3K/AKT/mTOR signaling pathways in human cancers. Life Sciences, 2020, 241, 117147.	4.3	43

#	ARTICLE	IF	CITATIONS
19	Response to: USP 26 regulates TGF β^2 signalling by deubiquitinating and stabilizing SMAD 7; not applicable in glioblastoma. EMBO Reports, 2020, 21, e47269.	4.5	2
20	AXL Is a Driver of Stemness in Normal Mammary Gland and Breast Cancer. IScience, 2020, 23, 101649.	4.1	20
21	OTUD4 enhances TGF β^2 signalling through regulation of the TGF β^2 receptor complex. Scientific Reports, 2020, 10, 15725.	3.3	7
22	Single-cell analysis of EphA clustering phenotypes to probe cancer cell heterogeneity. Communications Biology, 2020, 3, 429.	4.4	2
23	Identification of serum cytokine clusters associated with outcomes in ovarian clear cell carcinoma. Scientific Reports, 2020, 10, 18503.	3.3	4
24	Epithelial-to-Mesenchymal Transition is a Cause of Both Intrinsic and Acquired Resistance to KRAS G12C Inhibitor in KRAS G12C ⁺ Mutant Non-Small Cell Lung Cancer. Clinical Cancer Research, 2020, 26, 5962-5973.	7.0	118
25	SNAI1-Driven Sequential EMT Changes Attributed by Selective Chromatin Enrichment of RAD21 and GRHL2. Cancers, 2020, 12, 1140.	3.7	10
26	Development and Validation of the Gene Expression Predictor of High-grade Serous Ovarian Carcinoma Molecular SubTYPE (PrOTYPE). Clinical Cancer Research, 2020, 26, 5411-5423.	7.0	43
27	Whole Exome Sequencing of Multi-Regional Biopsies from Metastatic Lesions to Evaluate Actionable Truncal Mutations Using a Single-Pass Percutaneous Technique. Cancers, 2020, 12, 1599.	3.7	2
28	Inflammatory and mitogenic signals drive interleukin 23 subunit alpha (IL23A) secretion independent of IL12B in intestinal epithelial cells. Journal of Biological Chemistry, 2020, 295, 6387-6400.	3.4	25
29	A common MET polymorphism harnesses HER2 signaling to drive aggressive squamous cell carcinoma. Nature Communications, 2020, 11, 1556.	12.8	12
30	Cytoskeletal Proteins in Cancer and Intracellular Stress: A Therapeutic Perspective. Cancers, 2020, 12, 238.	3.7	70
31	AXL Targeting Abrogates Autophagic Flux and Induces Immunogenic Cell Death in Drug-Resistant Cancer Cells. Journal of Thoracic Oncology, 2020, 15, 973-999.	1.1	66
32	Targeting codon 158 p53-mutant cancers via the induction of p53 acetylation. Nature Communications, 2020, 11, 2086.	12.8	20
33	Integrative Analysis and Machine Learning Based Characterization of Single Circulating Tumor Cells. Journal of Clinical Medicine, 2020, 9, 1206.	2.4	42
34	Cysteine Deprivation Targets Ovarian Clear Cell Carcinoma <i>Via</i> Oxidative Stress and Iron-Sulfur Cluster Biogenesis Deficit. Antioxidants and Redox Signaling, 2020, 33, 1191-1208.	5.4	25
35	Characterization of circulating breast cancer cells with tumorigenic and metastatic capacity. EMBO Molecular Medicine, 2020, 12, e11908.	6.9	77
36	Super-Enhancer-Driven TOX2 Mediates Oncogenesis in Natural Killer/T Cell Lymphoma. Blood, 2020, 136, 17-17.	1.4	1

#	ARTICLE	IF	CITATIONS
37	Integrated use of bioinformatic resources reveals that co-targeting of histone deacetylases, IKBK and SRC inhibits epithelial-mesenchymal transition in cancer. <i>Briefings in Bioinformatics</i> , 2019, 20, 717-731.	6.5	20
38	The role of GRHL2 and epigenetic remodeling in epithelialâ€“mesenchymal plasticity in ovarian cancer cells. <i>Communications Biology</i> , 2019, 2, 272.	4.4	58
39	c-Met activation leads to the establishment of a TGFÎ²-receptor regulatory network in bladder cancer progression. <i>Nature Communications</i> , 2019, 10, 4349.	12.8	44
40	SNAI1 recruits HDAC1 to suppress SNAI2 transcription during epithelial to mesenchymal transition. <i>Scientific Reports</i> , 2019, 9, 8295.	3.3	31
41	Epithelial to mesenchymal transition (EMT) is associated with attenuation of succinate dehydrogenase (SDH) in breast cancer through reduced expression of SDHC. <i>Cancer & Metabolism</i> , 2019, 7, 6.	5.0	51
42	Bromodomain and extraterminal proteins foster the core transcriptional regulatory programs and confer vulnerability in liposarcoma. <i>Nature Communications</i> , 2019, 10, 1353.	12.8	39
43	Analysis of gene expression signatures identifies prognostic and functionally distinct ovarian clear cell carcinoma subtypes. <i>EBioMedicine</i> , 2019, 50, 203-210.	6.1	67
44	Pharmacological Inhibition of TFF3 Enhances Sensitivity of CMS4 Colorectal Carcinoma to 5-Fluorouracil through Inhibition of p44/42 MAPK. <i>International Journal of Molecular Sciences</i> , 2019, 20, 6215.	4.1	14
45	Molecular Subtypes of Urothelial Bladder Cancer: Results from a Meta-cohort Analysis of 2411 Tumors. <i>European Urology</i> , 2019, 75, 423-432.	1.9	205
46	The FZD 7â€“TWIST 1 axis is responsible for anoikis resistance and tumorigenesis in ovarian carcinoma. <i>Molecular Oncology</i> , 2019, 13, 757-780.	4.6	16
47	Decoding transcriptomic intraâ€“tumour heterogeneity to guide personalised medicine in ovarian cancer. <i>Journal of Pathology</i> , 2019, 247, 305-319.	4.5	18
48	Reply to Pontus Eriksson and Gottfrid SjÅrdahl's Letter to the Editor re: Tuan Zea Tan, Mathieu Rouanne, Kien Thiam Tan, Ruby Yun-Ju Huang, Jean-Paul Thiery. <i>Molecular Subtypes of Urothelial Bladder Cancer: Results from a Meta-cohort Analysis of 2411 Tumors. Eur Urol</i> 2019;75:423â€“32. <i>European Urology</i> , 2019, 75, e108-e109.	1.9	4
49	Non-canonical activation of Î²-catenin by PRL-3 phosphatase in acute myeloid leukemia. <i>Oncogene</i> , 2019, 38, 1508-1519.	5.9	17
50	Dual role of autophagy in hallmarks of cancer. <i>Oncogene</i> , 2018, 37, 1142-1158.	5.9	403
51	Xâ€“linked inhibitor of apoptosis inhibition sensitizes acute myeloid leukemia cell response to <sc>TRAIL</sc> and chemotherapy through potentiated induction of proapoptotic machinery. <i>Molecular Oncology</i> , 2018, 12, 33-47.	4.6	15
52	TGFÎ² Promotes Genomic Instability after Loss of RUNX3. <i>Cancer Research</i> , 2018, 78, 88-102.	0.9	22
53	DNA Methylation Profiling of Breast Cancer Cell Lines along the Epithelial Mesenchymal Spectrumâ€“Implications for the Choice of Circulating Tumour DNA Methylation Markers. <i>International Journal of Molecular Sciences</i> , 2018, 19, 2553.	4.1	15
54	BET Bromodomain inhibition promotes De-repression of TXNIP and activation of ASK1-MAPK pathway in acute myeloid leukemia. <i>BMC Cancer</i> , 2018, 18, 731.	2.6	16

#	ARTICLE	IF	CITATIONS
55	A loss-of-function genetic screening reveals synergistic targeting of AKT/mTOR and WTN/ β -catenin pathways for treatment of AML with high PRL-3 phosphatase. <i>Journal of Hematology and Oncology</i> , 2018, 11, 36.	17.0	22
56	RUNX Poly(ADP-Ribosyl)ation and BLM Interaction Facilitate the Fanconi Anemia Pathway of DNA Repair. <i>Cell Reports</i> , 2018, 24, 1747-1755.	6.4	27
57	The tumour suppressor OPCML promotes AXL inactivation by the phosphatase PTPRG in ovarian cancer. <i>EMBO Reports</i> , 2018, 19, .	4.5	30
58	NF- κ B promotes the stem-like properties of leukemia cells by activation of LIN28B. <i>World Journal of Stem Cells</i> , 2018, 10, 34-42.	2.8	8
59	Integrated molecular analysis of Asian ovarian cancer: Gene expression and whole exome sequencing analyses from the iPocc Translational Research study (TriPocc).. <i>Journal of Clinical Oncology</i> , 2018, 36, 5562-5562.	1.6	1
60	The immune checkpoint ligand PD-L1 is upregulated in EMT-activated human breast cancer cells by a mechanism involving ZEB-1 and miR-200. <i>Oncolmmunology</i> , 2017, 6, e1263412.	4.6	193
61	Acquisition of tumor cell phenotypic diversity along the EMT spectrum under hypoxic pressure: Consequences on susceptibility to cell-mediated cytotoxicity. <i>Oncolmmunology</i> , 2017, 6, e1271858.	4.6	61
62	Transposon insertional mutagenesis in mice identifies human breast cancer susceptibility genes and signatures for stratification. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2017, 114, E2215-E2224.	7.1	34
63	Belinostat exerts antitumor cytotoxicity through the ubiquitin-proteasome pathway in lung squamous cell carcinoma. <i>Molecular Oncology</i> , 2017, 11, 965-980.	4.6	31
64	Wanted DEAD/H or Alive: Helicases Winding Up in Cancers. <i>Journal of the National Cancer Institute</i> , 2017, 109, djw278.	6.3	79
65	<sc>USP</sc> 26 regulates <sc>TGF</sc> β 2 signaling by deubiquitinating and stabilizing <sc>SMAD</sc> 7. <i>EMBO Reports</i> , 2017, 18, 797-808.	4.5	54
66	LIN28B Activation by PRL-3 Promotes Leukemogenesis and a Stem Cell-like Transcriptional Program in AML. <i>Molecular Cancer Research</i> , 2017, 15, 294-303.	3.4	29
67	Targeting the AXL signaling pathway in ovarian cancer. <i>Molecular and Cellular Oncology</i> , 2017, 4, e1263716.	0.7	9
68	Loss of discoidin domain receptor 1 (DDR1) via CpG methylation during EMT in epithelial ovarian cancer. <i>Gene</i> , 2017, 635, 9-15.	2.2	20
69	β -Lnc β ing Wnt in female reproductive cancers: therapeutic potential of long non-coding RNAs in Wnt signalling. <i>British Journal of Pharmacology</i> , 2017, 174, 4684-4700.	5.4	62
70	Molecular characterization of breast cancer CTCs associated with brain metastasis. <i>Nature Communications</i> , 2017, 8, 196.	12.8	148
71	PPAR β Ligand-induced Annexin A1 Expression Determines Chemotherapy Response via Deubiquitination of Death Domain Kinase RIP in Triple-negative Breast Cancers. <i>Molecular Cancer Therapeutics</i> , 2017, 16, 2528-2542.	4.1	32
72	Clear Cell Renal Cell Carcinoma is linked to Epithelial-to-Mesenchymal Transition and to Fibrosis. <i>Physiological Reports</i> , 2017, 5, e13305.	1.7	36

#	ARTICLE	IF	CITATIONS
73	Inhibition of LIN28B impairs leukemia cell growth and metabolism in acute myeloid leukemia. <i>Journal of Hematology and Oncology</i> , 2017, 10, 138.	17.0	49
74	Identification of 42 Genes Linked to Stage II Colorectal Cancer Metastatic Relapse. <i>International Journal of Molecular Sciences</i> , 2016, 17, 598.	4.1	10
75	Functional characterization of selective exosite-binding inhibitors of matrix metalloproteinase-13 (MMP-13) – experimental validation in human breast and colon cancer. <i>Bioscience, Biotechnology and Biochemistry</i> , 2016, 80, 2122-2131.	1.3	7
76	“Normalizing” the malignant phenotype of luminal breast cancer cells via alpha(v)beta(3)-integrin. <i>Cell Death and Disease</i> , 2016, 7, e2491-e2491.	6.3	15
77	TIP60 inhibits metastasis by ablating DNMT1–SNAIL2-driven epithelial-mesenchymal transition program. <i>Journal of Molecular Cell Biology</i> , 2016, 8, 1-16.	3.3	17
78	A COL11A1-correlated pan-cancer gene signature of activated fibroblasts for the prioritization of therapeutic targets. <i>Cancer Letters</i> , 2016, 382, 203-214.	7.2	99
79	Manganese Superoxide Dismutase Expression Regulates the Switch Between an Epithelial and a Mesenchymal-Like Phenotype in Breast Carcinoma. <i>Antioxidants and Redox Signaling</i> , 2016, 25, 283-299.	5.4	42
80	TRPV4 Regulates Breast Cancer Cell Extravasation, Stiffness and Actin Cortex. <i>Scientific Reports</i> , 2016, 6, 27903.	3.3	98
81	The GAS6-AXL signaling network is a mesenchymal (Mes) molecular subtype–specific therapeutic target for ovarian cancer. <i>Science Signaling</i> , 2016, 9, ra97.	3.6	105
82	GRHL2-miR-200-ZEB1 maintains the epithelial status of ovarian cancer through transcriptional regulation and histone modification. <i>Scientific Reports</i> , 2016, 6, 19943.	3.3	119
83	Gelsolin-Cu/ZnSOD interaction alters intracellular reactive oxygen species levels to promote cancer cell invasion. <i>Oncotarget</i> , 2016, 7, 52832-52848.	1.8	18
84	Abstract A30: Frizzled-7 (FZD7)-mediated non-canonical Wnt-Planar Cell Polarity (PCP) signalling pathway as a novel molecular driver for the C5/Proliferative/Stem-A molecular subtype of ovarian cancer.., 2016, , .		0
85	Sustained Gas6/AXL signaling network in the mes subtype of ovarian cancer as a molecular subtype specific therapeutic target.. <i>Journal of Clinical Oncology</i> , 2016, 34, e17084-e17084.	1.6	0
86	Identification of AIM2 as a downstream target of JAK2V617F. <i>Experimental Hematology and Oncology</i> , 2015, 5, 2.	5.0	19
87	Highly sensitive and specific novel biomarkers for the diagnosis of transitional bladder carcinoma. <i>Oncotarget</i> , 2015, 6, 13539-13549.	1.8	64
88	CSIOVDB: a microarray gene expression database of epithelial ovarian cancer subtype. <i>Oncotarget</i> , 2015, 6, 43843-43852.	1.8	66
89	Non-invasive prenatal diagnostic testing for ð–thalassaemia using cell-free fetal DNA and next generation sequencing. <i>Prenatal Diagnosis</i> , 2015, 35, 258-265.	2.3	51
90	The clinical role of epithelial-mesenchymal transition and stem cell markers in advanced-stage ovarian serous carcinoma effusions. <i>Human Pathology</i> , 2015, 46, 1-8.	2.0	55

#	ARTICLE	IF	CITATIONS
91	Detection of aneuploidy from single fetal nucleated red blood cells using whole genome sequencing. <i>Prenatal Diagnosis</i> , 2015, 35, 637-644.	2.3	18
92	Short-term expansion of breast circulating cancer cells predicts response to anti-cancer therapy. <i>Oncotarget</i> , 2015, 6, 15578-15593.	1.8	134
93	Functional relevance of a six mesenchymal gene signature in epithelial-mesenchymal transition (EMT) reversal by the triple angiokinase inhibitor, nintedanib (BIBF1120). <i>Oncotarget</i> , 2015, 6, 22098-22113.	1.8	42
94	Abstract POSTER-TECH-1112: Quantitate epithelial-mesenchymal transition in ovarian cancer. , 2015, , .		0
95	Abstract POSTER-BIOL-1301: The receptor tyrosine kinase AXL modulates oncogenic signaling and epithelial mesenchymal transition in epithelial ovarian cancer. , 2015, , .		0
96	Abstract 1430: Transcriptional regulatory loops among SNAI1, TWIST1, ZEB1, and ZEB2 defines the epithelial-mesenchymal transition (EMT) spectrum in epithelial ovarian cancer (EOC). , 2015, , .		0
97	Utilization of the $\frac{1}{4}$ -Myc Mouse to Model Heterogeneity of Therapeutic Response. <i>Molecular Cancer Therapeutics</i> , 2014, 13, 3219-3229.	4.1	19
98	Phosphatase of regenerating liver-3 is regulated by signal transducer and activator of transcription 3 in acute myeloid leukemia. <i>Experimental Hematology</i> , 2014, 42, 1041-1052.e2.	0.4	21
99	Raf Kinase Inhibitory Protein Role in the Molecular Subtyping of Breast Cancer. <i>Journal of Cellular Biochemistry</i> , 2014, 115, 488-497.	2.6	9
100	Manganese Superoxide Dismutase Is a Promising Target for Enhancing Chemosensitivity of Basal-Like Breast Carcinoma. <i>Antioxidants and Redox Signaling</i> , 2014, 20, 2326-2346.	5.4	35
101	Epithelial-mesenchymal transition spectrum quantification and its efficacy in deciphering survival and drug responses of cancer patients. <i>EMBO Molecular Medicine</i> , 2014, 6, 1279-1293.	6.9	612
102	Disruption of Runx1 and Runx3 Leads to Bone Marrow Failure and Leukemia Predisposition due to Transcriptional and DNA Repair Defects. <i>Cell Reports</i> , 2014, 8, 767-782.	6.4	80
103	Lgr5 marks stem/progenitor cells in ovary and tubal epithelia. <i>Nature Cell Biology</i> , 2014, 16, 745-757.	10.3	187
104	DEAD-box helicase DP103 defines metastatic potential of human breast cancers. <i>Journal of Clinical Investigation</i> , 2014, 124, 3807-3824.	8.2	118
105	Molecular Integrative Clustering of Asian Gastric Cell Lines Revealed Two Distinct Chemosensitivity Clusters. <i>PLoS ONE</i> , 2014, 9, e111146.	2.5	2
106	SPHK1 regulates proliferation and survival responses in triple-negative breast cancer. <i>Oncotarget</i> , 2014, 5, 5920-5933.	1.8	64
107	A central role for TRPS1 in the control of cell cycle and cancer development. <i>Oncotarget</i> , 2014, 5, 7677-7690.	1.8	43
108	Abstract 1058: Grainyhead-like 2 regulates molecular subtype switching in epithelial ovarian cancer. , 2014, , .		0

#	ARTICLE	IF	CITATIONS
109	Epithelial-to-Mesenchymal Transition and Autophagy Induction in Breast Carcinoma Promote Escape from T-cellâ€ Mediated Lysis. <i>Cancer Research</i> , 2013, 73, 2418-2427.	0.9	255
110	Functional genomics identifies five distinct molecular subtypes with clinical relevance and pathways for growth control in epithelial ovarian cancer. <i>EMBO Molecular Medicine</i> , 2013, 5, 1051-1066.	6.9	235
111	EMT-Induced Stemness and Tumorigenicity Are Fueled by the EGFR/Ras Pathway. <i>PLoS ONE</i> , 2013, 8, e70427.	2.5	58
112	Protein Arginine Methyltransferase 6 Regulates Embryonic Stem Cell Identity. <i>Stem Cells and Development</i> , 2012, 21, 2613-2622.	2.1	47
113	Abstract 2979: Epithelial-mesenchymal gene expression signature defines clinically relevant subtypes in epithelial ovarian cancer. , 2012, , .		1
114	A Decision Making System Based on Complementary Learning. <i>Intelligent Systems Reference Library</i> , 2010, , 163-179.	1.2	1
115	Data mining analysis to validate performance tuning practices for HPL. , 2009, , .		5
116	Ovarian cancer diagnosis with complementary learning fuzzy neural network. <i>Artificial Intelligence in Medicine</i> , 2008, 43, 207-222.	6.5	44
117	A Novel Biologically and Psychologically Inspired Fuzzy Decision Support System: Hierarchical Complementary Learning. <i>IEEE/ACM Transactions on Computational Biology and Bioinformatics</i> , 2008, 5, 67-79.	3.0	11
118	Rainfall intensity prediction by a spatial-temporal ensemble. , 2008, , .		4
119	BIOLOGICAL BRAIN-INSPIRED GENETIC COMPLEMENTARY LEARNING FOR STOCK MARKET AND BANK FAILURE PREDICTION. <i>Computational Intelligence</i> , 2007, 23, 236-261.	3.2	45
120	Case study: Digital spatial profiling of metastatic clear cell carcinoma reveals intra-tumor heterogeneity in epithelial-mesenchymal gradient. , 0, , .		1